The US Food and Drug Administration should prevent drug companies from using background music during the section of drug advertisements that discuss the potential side effects and risks of the product, a new citizen petition demands, arguing the proposal is simply a more clear cut way for FDA to enforce goals it has already articulated for drug advertisements.
DTC Ads: Citizen Petition Pushes For Narrow But Strict Music Ban
KEI argues a wholesale ban on music during the presentation of risk information in drug ads would be a more clear-cut way for FDA to enforce its existing goals. Others say the ban goes much further than past FDA policy and enforcement.
More from US FDA
• By
Lowell Zeta, a senior counselor at the FDA from 2020 to 2021, returns as deputy commissioner for strategic initiatives. The agency also names a new acting CIO and acting CVM director, but OGD's Ted Sherwood and OPDP's Catherine Gray retired.
• By
Ascertaining the novelty and benefits of Makary’s new drug approval idea – along with what it would take to implement it – requires more clarity on the types of studies he envisions being used to grant and confirm “plausible mechanism’ approvals.
• By
In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.
• By
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
More from Agency Leadership
• By
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
• By
Tracy Beth Høeg, who is reportedly re-examining Novavax’s COVID vaccine application, is the FDA rep at the CDC panel’s first meeting under the Trump Administration. She raised concerns about routine use of Jynneos for adolescents at risk of mpox and questioned how Moderna assessed efficacy of its COVID vaccines.
• By
Plan to reorganize the agency into five offices was designed by someone who does not understand the FDA, former long-time agency official Janet Woodcock says. The proposal would eliminate highly specialized expertise in favor of “a big team of generalists,” former Principal Deputy Commissioner Joshua Sharfstein says.